Opportunities: UroGen Pharma Ltd (URGN) Stock in the Short-Term and the Long-Term

2d ago, source: bovnews

Jefferies lowered the price target for the UroGen Pharma Ltd (NASDAQ:URGN) stock from “a Buy” to “a Hold”. The rating was released on February 08, 2023, according to finviz. The research report from H ...

UroGen Pharma Holds Steady Amidst Financial Underperformance and Anticipated Study Results

4d ago, source:

Paul Choi, an analyst from Goldman Sachs, maintained the Hold rating on Urogen Pharma (URGN – Research Report). The associated price ...

UroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week

1mon ago, source: Yahoo Finance

Institutions' substantial holdings in UroGen Pharma implies that they have significant influence over the company's share price The top 9 shareholders own 50% of the company Insiders have been ...

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights

5d ago, source: Business Wire

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specia ...

Buy Rating Affirmed for Urogen Pharma as UGN-102 Progresses Towards FDA Approval and Market Success

5d ago, source:

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Urogen Pharma (URGN – Research Report), with a ...

UroGen Pharma Ltd URGN

10d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

UroGen Pharma Ltd.

19d ago, source: Wall Street Journal

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...